Impact of a whole food, plant-based diet on LDL-cholesterol and cardiovascular risk factors in adults with heterozygous familial hypercholesterolemia: a randomized, two-period, two-treatment, crossover, fully controlled feeding trial
Open Access
- 20 May 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder that accelerates atherosclerosis and leads to premature cardiovascular diseases (CVD). Whole food, plant-based diets (WFPB) are recommended worldwide for their cardioprotective properties but evidence regarding their effects in HeFH management remains unavailable. This study aims to evaluate the impact of a WFPB, in place of a standard American diet (SAD), on LDL-cholesterol (LDL-C) (primary outcome) and other CVD risk factors among adults with HeFH. In this randomized, two-period, two-treatment, crossover, controlled feeding trial, 50 adults with genetically confirmed HeFH, free of cholesterol-lowering medication, consumed a WFPB and a SAD for 4 weeks each in a random order, under fully controlled, isocaloric feeding conditions. The diets were separated by a two- to four-week washout period. LDL-C and other CVD risk factors were measured at the end of each diet. The WFPB induced a clinically significant reduction in LDL-C relative to the SAD ( − 17.9%, 95% CI: −21.7%, −14.3%; P < 0.0001). The study demonstrates the clinical significance of diet therapy in HeFH and supports its re-establishment as a cornerstone in clinical guidelines (clinicaltrials.gov registration: NCT05181553; funding: Canadian Institutes of Health Research).Keywords
Funding Information
- Canadian Institutes of Health Research (462540)
- Santé (310651)
This publication has 69 references indexed in Scilit:
- Association Between Healthy Eating Patterns and Risk of Cardiovascular DiseaseJAMA Internal Medicine, 2020
- Reducing the Clinical and Public Health Burden of Familial HypercholesterolemiaJAMA Cardiology, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 InhibitorClinical Pharmacokinetics, 2018
- Lipid Lowering with Soluble Dietary FiberCurrent Atherosclerosis Reports, 2016
- Metabolomics by Gas Chromatography–Mass Spectrometry: Combined Targeted and Untargeted ProfilingCurrent Protocols in Molecular Biology, 2016
- Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in HyperlipidemiaJAMA, 2011
- Effects of Diet and Simvastatin on Serum Lipids, Insulin, and Antioxidants in Hypercholesterolemic MenJAMA, 2002
- A Satiety Quotient: A Formulation to Assess the Satiating Effect of FoodAppetite, 1997
- Molecular genetics of the LDL receptor gene in familial hypercholesterolemiaHuman Mutation, 1992
- Lovastatin Efficacy in Reducing Low-Density Lipoprotein Cholesterol Levels on High- vs Low-Fat DietsJAMA, 1991